SERMONIX NEW LOGO JPEG (2).jpg
Sermonix to Host KOL Fireside Chat on Advancements in the Metastatic Breast Cancer Treatment Landscape on April 22, 2024
19. April 2024 16:26 ET | Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, April 19, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic...
Healis Therapeutics announces collaboration with Massachusetts General Hospital (MGH) and affiliates of Harvard Medical School to advance clinical-stage neuroscience research
26. März 2024 08:00 ET | Healis Therapeutics
The collaboration will focus on Healis’ clinical program studying the safety and efficacy of CKDB-501A, a BoNT/A neuromodulator, for neuropsychiatry.
Logo.png
Dr. Maurizio Fava of Massachusetts General Hospital to Serve as Principal Investigator for PT00114 Clinical Trial
16. Dezember 2020 09:15 ET | Protagenic Therapeutics, Inc.
Clinical Trials of First-in-Class Peptide to Commence in 1H 2021 NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (OTCQB: PTIX) announced today that Dr. Maurizio Fava,...
FluoroPharma Medical, Inc..png
FPMI Restructures CardioPET License With Massachusetts General Hospital
27. September 2018 09:00 ET | FluoroPharma Medical, Inc.
MONTCLAIR, NJ, Sept. 27, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- FluoroPharma Medical Inc. (OTCQB: FPMI) announced today that it has reached an agreement with The General Hospital Corporation,...
National Brain Tumor Society 2017 Scientific Summit Showcases Research & Treatment Development Opportunities in Neuro-Oncology Field
31. Oktober 2017 15:29 ET | National Brain Tumor Society
BOSTON, MA--(Marketwired - October 31, 2017) - National Brain Tumor Society (NBTS), the largest nonprofit dedicated to the brain tumor community in the United States, recently hosted its annual...
Editas-Logo-Small (1).jpg
Editas Medicine Announces Exclusive License to Advanced CRISPR Genome Editing Technology from Massachusetts General Hospital
03. August 2016 08:00 ET | Editas Medicine
-- License to Engineered Forms of Cas9 Nuclease Includes High-Fidelity Cas9 and Cas9 PAM Variants -- CAMBRIDGE, Mass., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a...
Vocera to Showcase E
Vocera to Showcase Enterprise Solutions for Communication and Collaboration at HIMSS16
18. Februar 2016 08:00 ET | Vocera Communications
SAN JOSE, Calif., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Vocera Communications, Inc. (NYSE:VCRA), the leading healthcare communications company, will showcase the Vocera Communication Platform at the...
Massachusetts Genera
Massachusetts General Hospital Improves Communication in Its Operating Rooms With Vocera
09. Dezember 2015 08:00 ET | Vocera Communications
SAN JOSE, Calif., Dec. 09, 2015 (GLOBE NEWSWIRE) -- Vocera Communications (NYSE:VCRA), the leading mobile healthcare communications company, announced today that Massachusetts General Hospital (MGH)...